Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | HPGD | P15428 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | PPARG | P37231 | 4/20 | 0.73 |
| ▸ | PPARD | Q03181 | 4/20 | 0.73 |
| ▸ | PPARA | Q07869 | 4/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | MAOB | P27338 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527919 | 0.89 | KDM4E (0.81) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL2069094 | 0.89 | KDM4E (0.81) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL10559664 | 0.85 | ALOX12 (0.63) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL4683689 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| 7-Hydroxy Isoflavone SCHEMBL762528 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL30015006 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL29651545 | 0.83 | MIF (0.61) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL8602 | 0.83 | MIF (0.61) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL13904559 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| 7-Hydroxy Isoflavone SCHEMBL5803559 | 0.82 | KDM4E (0.94) | KDM4EALDH1A1HSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026657-A1 | FLAVONOID PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-1412343-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | KDM4E 1318/4885ALDH1A1 4382/4885HSD17B10 349/4885 |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | KDM4E 1769/4885ALDH1A1 2695/4885HSD17B10 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.